Like a punch list after buying a new house, it’s finite, it’s known and it’s either fixed or it isn’t especially with the guidance they gotten over last several months . Shouldn’t take long at all ... then let the valuation take it where it may. IMHO
Given all the dynamics in play, I can’t see FDA approval going past February. This long delay will bode well for follow on complex molecules to not repeat similar manufacturing issues in other indications.
Extremely positive update which opens up synergistic opportunities through partnerships to advance quickly to be BC standard in early diagnosis plus solid good news for UR pathway for additional success and market opportunity. Ok by me to take another 2 months to get the manufacturing iron clad for approval.
Just think shorts are gambling The resubmission will be a lengthy protracted cycle allowing them to keep playing their little game longer. We shall see!